Metabolic Syndrome Criteria (IDF 2006)
IDF 2006 criteria for metabolic syndrome. Central obesity is required plus ≥2 of 4 additional criteria.
Score interpretation
No central obesity: Criteria not met regardless of other factors
→ Maintain healthy weight; lifestyle counselling
Central obesity present but <2 additional criteria
→ Central obesity present: weight loss target 5–10%; lifestyle modification; recheck lipids, BP, glucose annually
Central obesity + ≥2 additional criteria: Metabolic syndrome confirmed
→ Cardiovascular risk assessment; FINDRISC or Framingham; lifestyle intervention; treat individual components; consider referral
Interpretation bands for the Metabolic Syndrome. Apply clinical judgement and local guidance.
References
- Alberti KG, et al. The metabolic syndrome — a new worldwide definition. Lancet. 2005;366(9491):1059-1062.
Related
Curated clinical cross-links plus same-class fallbacks.
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Trimetazidine · Metabolic Anti-Anginal
- L-Carnitine · Antidote / Metabolic Agent
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.